Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Modeling Spinal Mobility in Ankylosing Spondylitis: Towards New Telekinetic Biomarkers

NCT: NCT05570656 · COMPLETED

NCT IDNCT05570656
StatusCOMPLETED
Start Date2022-12-13
Completion2023-09-14
SponsorUniversity Hospital, Montpellier (OTHER)
First posted
Last updated

Brief Summary

Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disease that mainly affects the spine and pelvis in its axial form. It is responsible for chronic inflammatory pain and sometimes ankylosis with significant functional retention. Clinicians need markers capable of precisely measuring the restriction of range of motion in these patients, reflections of the activity and/or sequelae of the disease. The Inverstigators validated movement markers in the AS by a device including inertial sensors (XSENS) and computer modeling. The accuracy and repeatability of the XSENS-Awinda system compared to the reference measurement system have been demonstrated. The XSENS-Awinda device offers new real-time evaluation possibilities for quantitative gait analysis. This opens the way to new diagnostic tools, prognostics and therapeutic perspectives for the clinician.

Frequently Asked Questions

What is Modeling Spinal Mobility in Ankylosing Spondylitis: Towards New Telekinetic Biomarkers?

Modeling Spinal Mobility in Ankylosing Spondylitis: Towards New Telekinetic Biomarkers is a clinical trial registered under NCT05570656. Current status: COMPLETED.

What is the status of NCT05570656?

The current status of NCT05570656 (Modeling Spinal Mobility in Ankylosing Spondylitis: Towards New Telekinetic Biomarkers) is: COMPLETED.

When did Modeling Spinal Mobility in Ankylosing Spondylitis: Towards New Telekinetic Biomarkers start?

Modeling Spinal Mobility in Ankylosing Spondylitis: Towards New Telekinetic Biomarkers started on 2022-12-13.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.